Calidi Biotherapeutics, Inc. (CLDI)
NYSEAMERICAN: CLDI · Real-Time Price · USD
0.224
-0.014 (-5.68%)
At close: Apr 28, 2026, 4:00 PM EDT
0.209
-0.015 (-6.52%)
Pre-market: Apr 29, 2026, 8:00 AM EDT
Calidi Biotherapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
29
Market Cap
2.47M
Revenue Chart
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| GeoVax Labs | 2.49M |
| Scinai Immunotherapeutics | 1.31M |
| Biodexa Pharmaceuticals | 104.90K |
| HCW Biologics | 54.23K |
| Virax Biolabs Group | 2.99K |
CLDI News
- 9 days ago - Calidi Biotherapeutics Presents New Data on Its Differentiated Approach to In Situ T-Cell Engagers Including a New Candidate Targeting TROP-2 at the AACR Annual Meeting in April 2026 - GlobeNewsWire
- 4 weeks ago - Calidi Biotherapeutics Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Operational Highlights - GlobeNewsWire
- 6 weeks ago - Calidi Biotherapeutics Presents its Innovative and Scalable Manufacturing Process for CLD-401 at the 9th Annual Bioprocessing Summit; FDA Feedback Support Company's Approach to Manufacturing - GlobeNewsWire
- 7 weeks ago - Calidi Biotherapeutics Announces Closing of $6.0 Million Underwritten Public Offering and Full Exercise of Underwriters' Over-Allotment Option - GlobeNewsWire
- 7 weeks ago - Calidi Biotherapeutics Announces Pricing of $5.2 Million Underwritten Public Offering - GlobeNewsWire
- 7 weeks ago - Calidi Biotherapeutics Announces Proposed Public Offering - GlobeNewsWire
- 2 months ago - Calidi Biotherapeutics Presents Data on its New Approach to Bispecific T-Cell Engagers (BiTEs) Using its RedTail Platform at the 2026 AACR-IO Conference - GlobeNewsWire
- 2 months ago - Calidi Biotherapeutics To Present on its New Approach to Bispecific T-Cell Engagers (BiTEs) Using its RedTail Platform in a Late-Breaking Abstract at the 2026 AACR-IO Conference - GlobeNewsWire